Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Anti-PSCA(dCH2)BBz-CAR T-cells |
Synonyms | |
Therapy Description |
Anti-PSCA(dCH2)BBz-CAR T-cells are T-cells that have been engineered to express a PSCA-targeted chimeric antigen receptor (CAR) containing a 4-1BB signaling domain and truncated CD19, which may increase death of PSCA-expressing tumor cells and and decrease tumor growth (PMID: 29308300). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Anti-PSCA(dCH2)BBz-CAR T-cells | anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T lymphocytes | Anti-PSCA(dCH2)BBz-CAR T-cells are T-cells that have been engineered to express a PSCA-targeted chimeric antigen receptor (CAR) containing a 4-1BB signaling domain and truncated CD19, which may increase death of PSCA-expressing tumor cells and and decrease tumor growth (PMID: 29308300). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03873805 | Phase I | Cyclophosphamide + Fludarabine Anti-PSCA(dCH2)BBz-CAR T-cells | PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer | Active, not recruiting | USA | 0 |
NCT05805371 | Phase I | Anti-PSCA(dCH2)BBz-CAR T-cells | PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | 0 |